- Effectiveness and Safety of Rivaroxaban Versus Warfarin among Nonvalvular Atrial Fibrillation Patients with Concomitant Obstructive Sleep Apnea
TH Open · 2023
- Negative effects of rivaroxaban observed in a patient with multiple common risks triggered by a bicycle accident
Clinical Case Reports · 2023
- Clinical and Economic Outcomes in Low-risk Pulmonary Embolism Patients Treated with Rivaroxaban versus Standard of Care
Journal of health economics and outcomes research · 2023
- Echocardiographic findings in infants of diabetic mothers and their relation to maternal glycemic control
Alexandria Journal of Pediatrics · 2023
- Cost-effectiveness of adding ezetimibe and/or PCSK9 inhibitors to high-dose statins for secondary prevention of cardiovascular disease in Chinese adults
International Journal of Technology Assessment in Health Care · 2023
- Characteristics and Effect of Rivaroxaban on Venous Thromboembolism in Korean Patients Compared to Western Population: A Subgroup Analysis from XALIA(-LEA) Study
Vascular Specialist International · 2022
- Comparative Effectiveness of Apixaban and Rivaroxaban Lead-in Dosing in VTE Treatment: Observational Multicenter Real-World Study
Journal of Clinical Medicine · 2022
- Identification of Secondary Prevention Patients Eligible for PCSK9 Inhibitors Therapy According to the Routine Clinical Practice in Spain
Advances in Therapy · 2022
- Drug–Drug Interaction between Antiplatelet Therapy and Lipid-Lowering Agents (Statins and PCSK9 Inhibitors)
Thrombosis and Haemostasis · 2022
- Restoring mortality data in the FOURIER cardiovascular outcomes trial of evolocumab in patients with cardiovascular disease: a reanalysis based on regulatory data
BMJ Open · 2022
- Rationale and design of COLchicine On-admission to Reduce inflammation in Acute Coronary Syndrome (COLOR-ACS) study
Journal of Cardiovascular Medicine · 2022
- Cost effectiveness of rivaroxaban versus warfarin among nonvalvular atrial fibrillation patients in Saudi Arabia: A Single–Center retrospective cohort study
Saudi Pharmaceutical Journal · 2022
- Atorvastatin ameliorates lipid overload-induced mitochondrial dysfunction and myocardial hypertrophy by decreasing fatty acid oxidation through inactivation of the p-STAT3/CPT1 pathway
Biomedicine & Pharmacotherapy · 2022
- Culprit vessel revascularization first with primary use of a dedicated transradial guiding catheter to reduce door to balloon time in primary percutaneous coronary intervention
Frontiers in Cardiovascular Medicine · 2022
- In-hospital initiation of PCSK9 inhibitor and short-term lipid control in patients with acute myocardial infarction
Lipids in Health and Disease · 2022
- The Effectiveness of Atorvastatin for the Prevention of Deep Vein Thrombosis in Cancer Patients Undergoing Chemotherapy
2022
- Comparing the Efficacy and Safety of Apixaban Versus Warfarin in Morbidly Obese Patients
Cureus · 2022
- Antithrombotic therapy in peripheral arterial disease
Frontiers in Cardiovascular Medicine · 2022
- Dual pathway inhibition as compared to acetylsalicylic acid monotherapy in relation to endothelial function in peripheral artery disease, a phase IV clinical trial
Frontiers in Cardiovascular Medicine · 2022
- Novel Insights into the Management of Patients with Very High Cardiovascular Risk Eligible for PCSK9 Inhibitor Treatment: Baseline Findings from the PERI-DYS Study
Cardiovascular Drugs and Therapy · 2022
- A systematic review and meta-analyses on the effects of atorvastatin on blood pressure and heart rate
European Heart Journal - Cardiovascular Pharmacotherapy · 2022
- Association between Genetic Polymorphisms and Bleeding in Patients on Direct Oral Anticoagulants
Pharmaceutics · 2022
- Effect of PCSK9 inhibitors on remnant cholesterol and lipid residual risk: The LIPID‐REAL registry
European Journal of Clinical Investigation · 2022
- Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease
Circulation · 2022
- Adenosine Triphosphate Exerts Cardioprotective Effect on High-Dose Atorvastatin-Induced Heart Damage in Rats
Erzincan Üniversitesi Fen Bilimleri Enstitüsü Dergisi · 2022
- Polypill Strategy in Secondary Cardiovascular Prevention
New England Journal of Medicine · 2022
- Case report: Drug-drug interaction between alectinib and apixaban in NSCLC
Current Problems in Cancer Case Reports · 2022
- Population Pharmacokinetics and Dose Optimization Based on Renal Function of Rivaroxaban in Thai Patients with Non-Valvular Atrial Fibrillation
Pharmaceutics · 2022
- Combined Semi-mechanistic Target-Mediated Drug Disposition and Pharmacokinetic–Pharmacodynamic Models of Alirocumab, PCSK9, and Low-Density Lipoprotein Cholesterol in a Pooled Analysis of Randomized Phase I/II/III Studies
European Journal of Drug Metabolism and Pharmacokinetics · 2022
- Hyporesponse to statin therapy among patients with acute coronary syndrome: prevalence, impact on the development of heart failure in a short-term follow-up
Russian Journal of Cardiology · 2022
- Statin and Postcardiac Surgery Atrial Fibrillation Prevention: A Systematic Review and Meta-Analysis
Journal of Cardiovascular Pharmacology · 2022
- The prevalence of hyperlipidemia and features of lipid-lowering therapy in patients with myocardial infarction according to the Russian register of acute myocardial infarction REGION-MI
Kardiologiia · 2022
- RNA Sequencing Reveals Beneficial Effects of Atorvastatin on Endothelial Cells in Acute Kawasaki Disease
Journal of the American Heart Association · 2022
- The influence of extremely high body weight (BMI > 35kg/ m2) on apixaban plasma concentration in patients with atrial fibrillation
2022
- Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER Trial
TH Open · 2022
- Enhanced-Dose Statins for ST-Segment Elevation Myocardial Infarction Patients after Emergency Percutaneous Coronary Intervention
Disease Markers · 2022
- [Atorvastatin inhibits malignant behaviors and induces apoptosis in human glioma cells by up-regulating miR-146a and inhibiting the PI3K/Akt signaling pathway].
2022
- Drug-Related Problems and Factors Involved in the Imbalance of Oral Anticoagulants in Lebanese Patients: A Cross.Sectional Study
Dr Sulaiman Al Habib Medical Journal · 2022
- Atorvastatin can delay arterial stiffness progression in hemodialysis patients
International Urology and Nephrology · 2022
- Differential Inhibition of Platelet Reactivity by Dual Therapy With Aspirin and Low-Dose Rivaroxaban in Peripheral Arterial Disease: A Pilot Study
Frontiers in Cardiovascular Medicine · 2022
- Synthesis and characterization of impurities of Apixaban drug substance—An anticoagulant
Journal of Heterocyclic Chemistry · 2022
- PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis
BMJ · 2022
- PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations
BMJ · 2022
- A modern approach to the treatment of cancer-associated venous thromboembolic complications: a lecture
Journal of Modern Oncology · 2022
- How to optimize treatment in patients with different forms of coronary artery disease
Meditsinskiy sovet = Medical Council · 2022
- Intensification of lipid-lowering therapy in very high-risk patients: potential of combination with PCSK9 inhibitors
Russian Journal of Cardiology · 2022
- Comparing the Effect of a Preprocedural Loading Dose of Atorvastatin vs. Rosuvastatin on the Prevalence of No-reflow and Low TIMI Flow in Patients with ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Intervention
Shiraz E-Medical Journal · 2022
- Anticoagulant monitoring of rivaroxaban by chromogenic anti-Xa assays and UHPLC-MS/MS in patients with atrial fibrillation
2022
- Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction
JAMA · 2022
- Clinical outcomes of direct-acting oral anticoagulants compared to warfarin in patients with non-valvular atrial fibrillation
Korean Journal of Clinical Pharmacy · 2022